Social, cultural and economic aspects of antimicrobial resistance

Affiliations

¹ Center for Advanced Studies in Biomedical Innovation Law, University of Copenhagen, Copenhagen, Denmark.
² Social Innovation on Drug Resistance, Boston University, Boston, United States of America (USA).
³ Global Strategy Lab, Faculty of Health and Osgoode Law School, York University, 4700 Keele Street, Dahdaleh Building, Suite 2120, Toronto, Ontario, M3J 1P3, Canada.
⁴ Max Planck Institute for Innovation and Competition, Munich, Germany.
⁵ Department of Global Health and Development, London School of Hygiene and Tropical Medicine, London, England.
⁶ Department of Business Studies, Uppsala University, Uppsala, Sweden.
⁷ Antimicrobial Stewardship Program, Geneva University Hospitals, Geneva, Switzerland.
⁸ Program on Regulation, Therapeutics, and Law, Harvard Medical School and Brigham and Women's Hospital, Boston University, Boston, USA.
⁹ Center for Disease Dynamics, Economics & Policy, Washington, DC, USA.
¹⁰ Centre for Law, Medicine and Life Sciences, University of Cambridge, Cambridge, England.
¹¹ Center for Infectious Disease Research and Policy, University of Minnesota, Minneapolis, USA.
¹² Milken Institute School of Public Health, George Washington University, Washington, DC, USA.

Editorial

Timo Minssen et al. Bull World Health Organ. 2020.

. 2020 Dec 1;98(12):823-823A.

doi: 10.2471/BLT.20.275875.

¹ Center for Advanced Studies in Biomedical Innovation Law, University of Copenhagen, Copenhagen, Denmark.
² Social Innovation on Drug Resistance, Boston University, Boston, United States of America (USA).
³ Global Strategy Lab, Faculty of Health and Osgoode Law School, York University, 4700 Keele Street, Dahdaleh Building, Suite 2120, Toronto, Ontario, M3J 1P3, Canada.
⁴ Max Planck Institute for Innovation and Competition, Munich, Germany.
⁵ Department of Global Health and Development, London School of Hygiene and Tropical Medicine, London, England.
⁶ Department of Business Studies, Uppsala University, Uppsala, Sweden.
⁷ Antimicrobial Stewardship Program, Geneva University Hospitals, Geneva, Switzerland.
⁸ Program on Regulation, Therapeutics, and Law, Harvard Medical School and Brigham and Women's Hospital, Boston University, Boston, USA.
⁹ Center for Disease Dynamics, Economics & Policy, Washington, DC, USA.
¹⁰ Centre for Law, Medicine and Life Sciences, University of Cambridge, Cambridge, England.
¹¹ Center for Infectious Disease Research and Policy, University of Minnesota, Minneapolis, USA.
¹² Milken Institute School of Public Health, George Washington University, Washington, DC, USA.

No abstract available

References

1. Chandler CIR. Current accounts of antimicrobial resistance: stabilisation, individualisation and antibiotics as infrastructure. Palgrave Commun. 2019. May 22;5(1):1–13. 10.1057/s41599-019-0263-4 - DOI - PMC - PubMed
1. Denyer Willis L, Chandler C. Quick fix for care, productivity, hygiene and inequality: reframing the entrenched problem of antibiotic overuse. BMJ Glob Health. 2019. August 15;4(4):e001590. 10.1136/bmjgh-2019-001590 - DOI - PMC - PubMed
1. Kesselheim AS, Outterson K. Improving antibiotic markets for long-term sustainability. Yale J Health Policy Law Ethics. 2011. Winter;11(1):101–67. - PubMed
1. Hoffman SJ, Outterson K. What will it take to address the global threat of antibiotic resistance? J Law Med Ethics. 2015. Summer;43(2):363–8. 10.1111/jlme.12253 - DOI - PubMed
1. Haenssgen MJ, Xayavong T, Charoenboon N, Warapikuptanun P, Khine Zaw Y. The consequences of AMR education and awareness raising: outputs, outcomes, and behavioural impacts of an antibiotic-related educational activity in Lao PDR. Antibiotics (Basel). 2018. November 1;7(4):95. 10.3390/antibiotics7040095 - DOI - PMC - PubMed